NeuroPace Inc — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
NeuroPace reported Q2 2026 revenue of $22.8M (RNS: $22.5M, up 21.3% YoY) and raised full-year 2026 total revenue guidance from $99-101M to $99.5-101.5M, reflecting 21-23% RNS growth. Net loss improved to ($6.2)M from ($10.0)M YoY; non-GAAP Adjusted EBITDA loss improved to ($2.8)M from ($4.9)M. Company launched ECoG Assistant AI tool, published 18-month NAUTILUS IGE data showing 77% median GTC seizure reduction, and expects FDA SIR meeting on track for IGE PMA supplement.
Why this rating
Modest revenue raise on $306M market cap; operational leverage improving (losses shrinking). IGE expansion pending FDA approval is upside, not yet material. Execution on plan, not transformational.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.